...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: New shares issued?

I found it interesting in that the price was $2.60 CAD which is approximately 2.00 USD in todays exchange markets.

As far as I am concerned that means that a real valuation for ZCC is 2.60 CAD as demonstrated by real buyers. I can only see it going up in future never mind that my brokers statement values my shares at 0.659.

I also am curious about the additional shares which are likely to be issued in the near future.

I, unlike some, do not want to see a sell to BP as I want to gain future income from distribution as Zenith receives royalty and other income from RVX and from Zenith Epigenetics Ltd.

I hold my shares of Zenith and much of my RVX shares in my TFSA and drawings from it are happily tax free.

Unfortunately I cannot contribute more to my TFSA till next year and then only the small amount allowed

Share
New Message
Please login to post a reply